ONCAlert | Upfront Therapy for mRCC
Videos  >  

Next Steps for CAR T Cells in B-Cell Lymphomas

Victor A. Chow, MD
Published Online:10:36 PM, Tue February 19, 2019


Victor A. Chow, MD, a senior hematology/oncology fellow at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discussed the next steps for chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell lymphomas.

The use of CAR T cells has been exciting in the field. Chow says this excitement has led to a lot of research and money investigating its potential in various settings. While CAR T cells have been approved for treatment of individuals after 2 or more lines of therapy, studies are now looking at moving this to the upfront setting.

Prospective trials comparing CAR T cells to autologous stem cell transplant will help determine which treatment a relapsed patient should receive. Chow expects to have a better understanding from these data in the next year or so.

See more from this study.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.